Novel strategies for anterior segment ocular drug delivery

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 106-123

  Cholkar, Kishore ^a   Patel, Sulabh P ^a   Vadlapudi, Aswani Dutt ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACICLOVIR; BETA CYCLODEXTRIN; DEXAMETHASONE; DICLOFENAC; DRUG ADDITIVE; EUDRAGIT RS; FLURBIPROFEN; GAMMA CYCLODEXTRIN; GANCICLOVIR; HYDROXYMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; INDOMETACIN; METHYLCELLULOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIOSOME; PILOCARPINE; POLOXAMER; POLY[N (2 HYDROXYETHYL)ASPARTAMIDE]; POLYSORBATE 80; POLYVINYL ALCOHOL; PRODRUG; TIMOLOL; TOLMETIN; VALACICLOVIR; VALGANCICLOVIR; VOCLOSPORIN;

ANTERIOR EYE SEGMENT; CONJUNCTIVA; CONTROLLED RELEASE FORMULATION; CORNEA; CORNEA TRANSPLANTATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; HUMAN; KERATITIS; MICELLIZATION; NANOTECHNOLOGY; NONHUMAN; OPEN ANGLE GLAUCOMA; REVIEW; VISUAL DISORDER;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTERIOR EYE SEGMENT; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; NANOTECHNOLOGY; PRODRUGS;

EID: 84875021551     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0200     Document Type: Review

References (167)

1. McCannel, C.A., Holland, G.N., Helm, C.J., Cornell, P.J., Winston, J.V., & Rimmer, T.G. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am. J. Ophthalmol. 121:35-46, 1996.
2. Ueta, M., & Kinoshita, S. Ocular surface inflammation is regulated by innate immunity. Prog. Retin. Eye Res. 31: 551-575, 2012.
3. Stein-Streilein, J., & Streilein, J.W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int. Rev. Immunol. 21:123-152, 2002.
4. Lapalus, P., Moulin, G., Bayer, V., Fredj-Reygrobellet, D., and Elena, P.P. Effects of a new anti-Allergic agent: the magnesium salt of N-Acetyl-Aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye. Curr. Eye Res. 5:517-522, 1986.
5. Ferguson, V.M., & Spalton, D.J. Recovery of the bloodaqueous barrier after cataract surgery. Br. J. Ophthalmol. 75: 106-110, 1991.
6. Abelson, M.B., & Schaefer, K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv. Ophthalmol. 38 Suppl:115-132, 1993.
7. Aswani Dutt Vadlapudi, A.P., Cholkar, K., & Ashim, K. Mitra recent patents on emerging therapeutics for the treatment of glaucoma, age related macular degeneration and uveitis. Recent Pat. Biomed. Eng. 5:83-101, 2012.
8. Duvvuri, S., Majumdar, S., & Mitra, A.K. Role of metabolism in ocular drug delivery. Curr. Drug Metab. 5:507-515, 2004.
9. Dartt, D.A. Regulation of mucin and fluid secretion by conjunctival epithelial cells. Prog. Retin. Eye Res. 21:555-576, 2002.
10. Lee, V.H., & Robinson, J.R. Prelminary examination of rabbit conjunctival mucins. J. Pharm. Sci. 69:430-438, 1980.
11. Srinivasan, B.D., Jakobiec, F.A., & Iwamoto, T. Conjunctiva. Philadelphia: Harper and Row; 1982.
12. Shi, X.P., & Candia, O.A. Active sodium and chloride transport across the isolated rabbit conjunctiva. Curr. Eye Res. 14:927-935, 1995.
13. Huang, A.J., Tseng, S.C., & Kenyon, K.R. Paracellular permeability of corneal and conjunctival epithelia. Invest. Ophthalmol. Vis. Sci. 30:684-689, 1989.
14. Horibe, Y., Hosoya, K., Kim, K.J., Ogiso, T., & Lee, V.H. Polar solute transport across the pigmented rabbit conjunctiva: size dependence and the influence of 8-bromo cyclic adenosine monophosphate. Pharm. Res. 14:1246-1251, 1997.
15. Hamalainen, K.M., Kananen, K., Auriola, S., Kontturi, K., and Urtti, A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Vis. Sci. 38:627-634, 1997.
16. Gukasyan, H.J., Yerxa, B.R., Pendergast, W., & Lee, V.H. Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells. Adv. Exp. Med. Biol. 506:255-259, 2002.
17. Yang, J.J., Kim, K.J., & Lee, V.H. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm. Res. 17:533-538, 2000.
18. Azartash, K., Kwan, J., Paugh, J.R., Nguyen, A.L., Jester, J.V., & Gratton, E. Pre-corneal tear film thickness in humans measured with a novel technique. Mol. Vis. 17:756-767, 2011.
19. Prydal, J.I., & Campbell, F.W. Study of precorneal tear film thickness and structure by interferometry and confocal microscopy. Invest. Ophthalmol. Vis. Sci. 33:1996-2005, 1992.
20. Prydal, J.I., Muir, M.G., & Dilly, P.N. Comparison of tear film thickness in three species determined by the glass fibre method and confocal microscopy. Eye (Lond). 7(Pt 3):472-475, 1993.
21. Mishima, S., Gasset, A., Klyce, S.D., Jr., & Baum, J.L. Determination of tear volume and tear flow. Invest. Ophthalmol. 5:264-276, 1966.
22. Scherz, W., Doane, M.G., & Dohlman, C.H. Tear volume in normal eyes and keratoconjunctivitis sicca. Albrecht Von Graefes Arch. Klin. Exp Ophthalmol. 192:141-150, 1974.
23. Holly, F.J., & Lemp, M.A. Tear physiology and dry eyes. Surv. Ophthalmol. 22:69-87, 1977.
24. van Setten, G.B., Schultz, G.S., & Macauley, S. Growth factors in human tear fluid and in lacrimal glands. Adv. Exp. Med. Biol. 350:315-319, 1994.
25. Ohashi, Y., Motokura, M., Kinoshita, Y., Mano, T., Watanabe, H., Kinoshita, S., Manabe, R., Oshiden, K., and Yanaihara, C. Presence of epidermal growth factor in human tears. Invest. Ophthalmol. Vis. Sci. 30:1879-1882, 1989.
26. van Setten, G.B., Tervo, T., Viinikka, L., Perheentupa, J., and Tarkkanen, A. Epidermal growth factor in human tear fluid: a minireview. Int. Ophthalmol. 15:359-362, 1991.
27. Prost, M. [Formation and structure of lacrimal film on the ocular surface]. Klin. Oczna. 91:29-31, 1989.
28. Hopkins, G.A., & Pearson R.M. General Pharmacological Principles. United Kingdom, Oxford: Butterworth-Heinemann; 1988.
29. Hitoshi Sasaki, K.Y., Nishida, K., Nakamura, J., and Ichikawa, M. Delivery of drugs to the eye by topical application. Prog. Retin. Eye Res. 15:583-620, 1996.
30. Schoenwald, R.D. Ocular drug delivery. Pharmacokinetic considerations. Clin. Pharmacokinet. 18:255-269, 1990.
31. Lee, V.H., & Robinson, J.R. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2:67-108, 1986.
32. Chrai, S.S., Patton, T.F., Mehta, A., & Robinson, J.R. Lacrimal and instilled fluid dynamics in rabbit eyes. J. Pharm. Sci. 62:1112-1121, 1973.
33. Chrai, S.S., Makoid, M.C., Eriksen, S.P., & Robinson, J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci. 63:333-338, 1974.
34. Ahmed, I. The Noncorneal Route in Ocular Drug Delivery. New York: Marcel Dekker, Inc.; 2003.
35. Rozsa, A.J., & Beuerman, R.W. Density and organization of free nerve endings in the corneal epithelium of the rabbit. Pain. 14:105-120, 1982.
36. Hornof, M., Toropainen, E., & Urtti, A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60:207-225, 2005.
37. Huang, H.S. Corneal penetration behavior of beta-blocking agents III: in vitro-in vivo correlation. J. Pharm. Sci. 72:1279-1281, 1983.
38. Jorge, F. The Corneal Endothelium. Elsevier, Amsterdam, the Netherlands; 2005.
39. Karla, P.K., Earla, R., Boddu, S.H., Johnston, T.P., Pal, D., and Mitra, A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr. Eye Res. 34:1-9, 2009.
40. Karla, P.K., Pal, D., Quinn, T., & Mitra, A.K. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int. J. Pharm. 336:12-21, 2007.
41. Karla, P.K., Pal, D., & Mitra, A.K. Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp. Eye Res. 84:53-60, 2007.
42. Dey, S., Patel, J., Anand, B.S., Jain-Vakkalagadda, B., Kaliki, P., Pal, D., Ganapathy, V., & Mitra, A.K. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci. 44:2909-2918, 2003.
43. Kaur, I.P., & Kanwar, M. Ocular preparations: the formulation approach. Drug Dev. Ind. Pharm. 28:473-493, 2002.
44. Anand, B.S., Dey, S., & Mitra, A.K. Current prodrug strategies via membrane transporters/receptors. Expert Opin. Biol. Ther. 2:607-620, 2002.
45. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Jarvinen, T., & Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7:255-270, 2008.
46. Majumdar, S., & Mitra, A.K. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin. Drug Deliv. 3:511-527, 2006.
47. Majumdar, S., Duvvuri, S., & Mitra, A.K. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 56:1437-1452, 2004.
48. Stratford, R.E., Jr., & Lee, V.H. Ocular aminopeptidase activity and distribution in the albino rabbit. Curr. Eye Res. 4:995-999, 1985.
49. Lee, V.H. Esterase activities in adult rabbit eyes. J. Pharm. Sci. 72:239-244, 1983.
50. Talluri, R.S., Hariharan, S., Karla, P.K., & Mitra, A.K. "Drug delivery to cornea and conjunctiva-esterase and protease directed prodrug design, in Ocular Periphery and Disorders," Series Editor: Darlene A. Dartt, Peter Bex, Patricia D'Amore, Reza Dana, Linda Mcloon & Jerry Niederkorn, San Deigo, California, USA: Elsevier, Academic Press; 42-53, 2011.
51. Chien, D.S., Tang-Liu, D.D., & Woodward, D.F. Ocular penetration and bioconversion of prostaglandin F2alpha prodrugs in rabbit cornea and conjunctiva. J. Pharm. Sci. 86:1180-1186, 1997.
52. Chien, D.S., Sasaki, H., Bundgaard, H., Buur, A., & Lee, V.H. Role of enzymatic lability in the corneal and conjunctival penetration of timolol ester prodrugs in the pigmented rabbit. Pharm. Res. 8:728-733, 1991.
53. Chang, S.C., Bundgaard, H., Buur, A., & Lee, V.H. Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load. Invest. Ophthalmol. Vis. Sci. 28:487-491, 1987.
54. Hughes, P.M., & Mitra, A.K. Effect of acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 2¢-esters in rabbit epithelial keratitis. J. Ocul. Pharmacol. 9:299-309, 1993.
55. Hughes, P.M., Krishnamoorthy, R., & Mitra, A.K. Effect of acylation on the ocular disposition of acyclovir. I: Synthesis, physicochemical properties, and antiviral activity of 2¢-esters. J. Ocul. Pharmacol. 9:287-297, 1993.
56. Anand, B.S., & Mitra, A.K. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. 19:1194-1202, 2002.
57. Gunda, S., Hariharan, S., & Mitra, A.K. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J. Ocul. Pharmacol. Ther. 22:465-476, 2006.
58. Katragadda, S., Talluri, R.S., & Mitra, A.K. Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J. Ocul. Pharmacol. Ther. 22:110-120, 2006.
59. Vadlapudi, A.D., Vadlapatla, R.K., & Mitra, A.K. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents. Recent Pat. Antiinfect. Drug Discov. 7:8-18, 2012.
60. Majumdar, S., Nashed, Y.E., Patel, K., Jain, R., Itahashi, M., Neumann, D.M., Hill, J.M., & Mitra, A.K. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. 21:463-474, 2005.
61. Anand, B., Nashed, Y., & Mitra, A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr. Eye Res. 26:151-163, 2003.
62. Katragadda, S., Talluri, R.S., Pal, D., & Mitra, A.K. Identification and characterization of a Na + -dependent neutral amino acid transporter, ASCT1, in rabbit corneal epithelial cell culture and rabbit cornea. Curr. Eye Res. 30:989-1002, 2005.
63. Jain-Vakkalagadda, B., Pal, D., Gunda, S., Nashed, Y., Ganapathy, V., & Mitra, A.K. Identification of a Na + -dependent cationic and neutral amino acid transporter, B(0, +), in human and rabbit cornea. Mol. Pharm. 1:338-346, 2004.
64. Jain-Vakkalagadda, B., Dey, S., Pal, D., & Mitra, A.K. Identification and functional characterization of a Na + -independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest. Ophthalmol. Vis. Sci. 44:2919-2927, 2003.
65. Katragadda, S., Gunda, S., Hariharan, S., & Mitra, A.K. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Int. J. Pharm. 359:15-24, 2008.
66. Civiale, C., Bucaria, F., Piazza, S., Peri, O., Miano, F., and Enea, V. Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems. J. Ocul. Pharmacol. Ther. 20:75-84, 2004.
67. Horibe, Y., Hosoya, K., Kim, K.J., & Lee, V.H. Carriermediated transport of monocarboxylate drugs in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. 39: 1436-1443, 1998.
68. Turner, H.C., Alvarez, L.J., Bildin, V.N., & Candia, O.A. Immunolocalization of Na-K-ATPase, Na-K-Cl and Naglucose cotransporters in the conjunctival epithelium. Curr. Eye Res. 21:843-850, 2000.
69. Hosoya, K., Lee, V.H., & Kim, K.J. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm. 60:227-240, 2005.
70. Prausnitz, M.R., & Noonan, J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87:1479-1488, 1998.
71. Vulovic, N., Primorac, M., Stupar, M., Brown, M.W., and Ford, J.L. Some studies on the preservation of indometacin suspensions intended for ophthalmic use. Pharmazie. 45: 678-679, 1990.
72. Meseguer, G., Buri, P., Plazonnet, B., Rozier, A., & Gurny, R. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J. Ocul. Pharmacol. Ther. 12:481-488, 1996.
73. Lapcik, L., Jr., Lapcik, L., De Smedt, S., Demeester, J., and Chabrecek, P. Hyaluronan: preparation, structure, properties, and applications. Chem. Rev. 98:2663-2684, 1998.
74. Kaur, I.P., & Smitha, R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev. Ind. Pharm. 28:353-369, 2002.
75. Gebhardt, B.M., Varnell, E.D., & Kaufman, H.E. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J. Ocul. Pharmacol. Ther. 11:509-517, 1995.
76. Dimitrova, E., Bogdanova, S., Mitcheva, M., Tanev, I., and Minkov, E. Development of model aqueous ophthalmic solution of indomethacin. Drug Dev. Ind. Pharm. 26:1297-1301, 2000.
77. Chetoni, P., Panichi, L., Burgalassi, S., Benelli, U., and Saettone, M.F. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J. Ocul. Pharmacol. Ther. 16:363-372, 2000.
78. Bucolo, C., & Spadaro, A. Pharmacological evaluation of anti-inflammatory pyrrole-Acetic acid derivative eye drops. J. Ocul. Pharmacol. Ther. 13:353-361, 1997.
79. Gao, Y., Sun, Y., Ren, F., & Gao, S. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev. Ind. Pharm. 36:1131-1138, 2010.
80. Chen, X., Li, X., Zhou, Y., Wang, X., Zhang, Y., Fan, Y., Huang, Y., & Liu, Y. Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: preparation, characterization, and in vivo evaluation. J. Biomater. Appl. 27:391-402, 2012.
81. Qian, Y., Wang, F., Li, R., Zhang, Q., & Xu, Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev. Ind. Pharm. 36:1340-1347, 2010.
82. Boddu, S.H., Jwala, J., Vaishya, R., Earla, R., Karla, P.K., Pal, D., & Mitra, A.K. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J. Ocul. Pharmacol. Ther. 26:37-48, 2010.
83. Yin, H., Gong, C., Shi, S., Liu, X., Wei, Y., & Qian, Z. Toxicity evaluation of biodegradable and thermosensitive PEG-PCL-PEG hydrogel as a potential in situ sustained ophthalmic drug delivery system. J. Biomed. Mater. Res. B Appl. Biomater. 92:129-137, 2010.
84. Cao, Y., Zhang, C., Shen, W., Cheng, Z., Yu, L.L., & Ping, Q. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J. Control. Release. 120:186-194, 2007.
85. Gratieri, T., Gelfuso, G.M., de Freitas, O., Rocha, E.M., and Lopez, R.F. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/ chitosan in situ forming gel. Eur. J. Pharm. Biopharm. 79:320-327, 2011.
86. Gupta, H., Jain, S., Mathur, R., Mishra, P., Mishra, A.K., and Velpandian, T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 14:507-515, 2007.
87. Cao, F., Zhang, X., & Ping, Q. New method for ophthalmic delivery of azithromycin by poloxamer/ carbopol-based in situ gelling system. Drug Deliv. 17:500-507, 2010.
88. Valls, R., Vega, E., Garcia, M.L., Egea, M.A., & Valls, J.O. Transcorneal permeation in a corneal device of nonsteroidal anti-inflammatory drugs in drug delivery systems. Open Med. Chem. J. 2:66-71, 2008.
89. Loftsson T SH, Hreinsdottir, D., Konradsdottir, F., and Stefansson, E. Dexamethasone delivery to posterior segment of the eye. J Incl. Phenom. Macrocycl. Chem. 57:585-589, 2007.
90. Loftsson, T., & Stefánsson, E. Cyclodextrin nanotechnology for ophthalmic drug delivery. US7893040; 2011.
91. Kararli, T.T., Bandyopadhyay, R., Singh, S.K., & Hawley, L.C. Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug. WO02005815; 2002.
92. Bary, A.R., Tucker, I.G., & Davies, N.M. Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur. J. Pharm. Biopharm. 50:237-244, 2000.
93. Kristinsson, J.K., Fridriksdottir, H., Thorisdottir, S., Sigurdardottir, A.M., Stefansson, E., & Loftsson, T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest. Ophthalmol. Vis. Sci. 37:1199-1203, 1996.
94. Cholkar, K., Patel, A., Vadlapudi, A.D., & Mitra, A.K. Novel Nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat. Nanomed. 2:82-95, 2012.
95. Patel, S., & Mitra, A.K. An overview of recent patents on nanocarrier based ophthalmic drug delivery systems. Recent Pat. Nanomed. 2:2-16, 2012.
96. Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., and Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 16:53-61, 2002.
97. Pignatello, R., Bucolo, C., Spedalieri, G., Maltese, A., and Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 23:3247-3255, 2002.
98. Liaw, Y.R.J., & Robinson, J.R. The effect of drug charge type and charge density on corneal transport. Int. J. Pharm. 88:111-124, 1992.
99. Rojanasakul, Y., Wang, L.Y., Bhat, M., Glover, D.D., Malanga, C.J., & Ma, J.K. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res. 9:1029-1034, 1992.
100. Calvo, P., Vila-Jato, J.L., & Alonso, M.J. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J. Pharm. Sci. 85:530-536, 1996.
101. Vega, E., Egea, M.A., Valls, O., Espina, M., & Garcia, M.L. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci. 95:2393-2405, 2006.
102. De Campos, A.M., Sanchez, A., & Alonso, M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224:159-168, 2001.
103. Yuan, X.B., Li, H., & Yuan, Y.B. Preparation of cholesterol-modified chitosan self-Aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr. Polym. 65:337-345, 2006.
104. Yuan, X.B., Yuan, Y.B., Jiang, W., Liu, J., Tian, E.J., Shun, H.M., Huang, D.H., Yuan, X.Y., Li, H., & Sheng, J. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int. J. Pharm. 349:241-248, 2008.
105. Ibrahim, H.K., El-Leithy, I.S., & Makky, A.A. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol. Pharm. 7:576-585, 2010.
106. Alonso, F.M.J., Calvo S.P., Remunan, L.C., & Vila, J.J.L. Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes. EP0771566; 2006.
107. Mitra, A.K., & Mishra, G.P. Pentablock polymers, U.S. 2011/0250283 A1; 2010.
108. Contreras-Ruiz, L., de la Fuente, M., Parraga, J.E., Lopez-Garcia, A., Fernandez, I., Seijo, B., Sanchez, A., Calonge, M., & Diebold, Y. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol. Vis. 17:279-290, 2011.
109. de la Fuente, M., Seijo, B., & Alonso, M.J. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 49:2016-2024, 2008.
110. Enriquez de Salamanca, A., Diebold, Y., Calonge, M., Garcia-Vazquez, C., Callejo, S., Vila, A., & Alonso, M.J. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest. Ophthalmol. Vis. Sci. 47:1416-1425, 2006.
111. Kompella, U.B., Sundaram, S., Raghava, S., & Escobar, E.R. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol. Vis. 12:1185-1198, 2006.
112. Di Tommaso, C., Torriglia, A., Furrer, P., Behar-Cohen, F., Gurny, R., & Moller, M. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int. J. Pharm. 416:515-524, 2011.
113. Pepic, I., Hafner, A., Lovric, J., Pirkic, B., & Filipovic-Grcic, J. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. J. Pharm. Sci. 99:4317-4325, 2010.
114. Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., and Mazzone,M.G. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int. J. Pharm. 378:177-186, 2009.
115. Tong, Y.C., Chang, S.F., Liu, C.Y., Kao, W.W., Huang, C.H., and Liaw, J. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J. Gene Med. 9:956-966, 2007.
116. Usui, T., Sugisaki, K., Amano, S., Jang, W.D., Nishiyama, N., & Kataoka, K. New drug delivery for corneal neovascularization using polyion complex micelles. Cornea. 24:S39-S42, 2005.
117. Pepic, I., Jalsenjak, N., & Jalsenjak, I. Micellar solutions of triblock copolymer surfactants with pilocarpine. Int. J. Pharm. 272:57-64, 2004.
118. Liaw, J., Chang, S.F., & Hsiao, F.C. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPOPEO) polymeric micelles. Gene Ther. 8:999-1004, 2001.
119. Gupta, A.K., Madan, S., Majumdar, D.K., & Maitra, A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. Int. J. Pharm. 209:1-14, 2000.
120. Velagaleti, P.R., Anglade, E., Khan, J., Gilger, B.C., and Mitra, A.K. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye. Drug Deliv. Technol. 10:43-47, 2010.
121. Mitra, A.K., Velagaleti, P.R., & Natesan, S. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, US2011/0300195 A1; 2011.
122. Sanders, D.R., Goldstick, B., Kraff, C., Hutchins, R., Bernstein, M.S., & Evans, M.A. Aqueous penetration of oral and topical indomethacin in humans. Arch. Ophthalmol. 101:1614-1616, 1983.
123. Kassem, M.A., Abdel Rahman, A.A., Ghorab, M.M., Ahmed, M.B., & Khalil, R.M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340:126-133, 2007.
124. Quintana-Hau, J.D., Cruz-Olmos, E., Lopez-Sanchez, M.I., Sanchez-Castellanos, V., Baiza-Duran, L., Gonzalez, J.R., Tornero, M., Mondragon-Flores, R., & Hernandez-Santoyo, A. Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno. Drug Dev. Ind. Pharm. 31:263-269, 2005.
125. Santipharp, P., & Alani Laman, L. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor. WO 2006/062875; 2006.
126. Badawi, A.A., El-Laithy, H.M., El Qidra, R.K., El Mofty, H., and El dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res. 31:1040-1049, 2008.
127. Gan, L., Gan, Y., Zhu, C., Zhang, X., & Zhu, J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int. J. Pharm. 365:143-149, 2009.
128. Baydoun, L., & Muller-Goymann, C.C. Influence of noctenylsuccinate starch on in vitro permeation of sodium diclofenac across excised porcine cornea in comparison to Voltaren ophtha. Eur. J. Pharm. Biopharm. 56:73-79, 2003.
129. ShaulMuchtar, M., Frucht-Pery, J., & Benita, S. Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J. Control. Release. 44 55-64, 1997.
130. Benita, S., & Lambert, G. Method and composition for dry eye treatment. US0108626; 2003.
131. Gan, Y., Gan, L., Shen, J., & Zhu, C. A Ophthalmic flurbiprofen ester nano-emulsion in situ gel formulation and the preparation method thereof. WO2010048788; 2010.
132. http://www.clinicaltrials.gov/ct2/show/NCT00814515, Double-masked trial of NOVA22007 (Ciclosporin 0.1%) versus vehicle in patients with moderate to severe dry eye syndrome. Last update: 11-27-2012.
133. http://clinicaltrials.gov/ct2/show/NCT00328653, Efficacy and tolerance of Nova22007 versus vehicle in patients with vernal keratoconjunctivitis (VKC). Last update: 11-27-2012.
134. Law, S.L., Huang, K.J., & Chiang, C.H. Acyclovircontaining liposomes for potential ocular delivery. Corneal penetration and absorption. J Control. Release. 63:135-140, 2000.
135. Sun, Y., Fox, T., Adhikary, G., Kester, M., & Pearlman, E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J. Leukoc. Biol. 83:1512-1521, 2008.
136. Arakawa, Y., Hashida, N., Ohguro, N., Yamazaki, N., Onda, M., Matsumoto, S., Ohishi, M., Yamabe, K., Tano, Y., and Kurokawa, N. Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice. Biomed. Res. 28:331-334, 2007.
137. Hirai, M., Minematsu, H., Kondo, N., Oie, K., Igarashi, K., and Yamazaki, N. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem. Biophys. Res. Commun. 353:553-558, 2007.
138. Yamazaki, N., Kojima, S., & Yokoyama, H. Biomedical nanotechnology for active drug delivery system by applying sugar-chain molecular functions. Curr. Appl. Phys. 5:112-117, 2005.
139. Prabu, P., Chaudhari, A.A., Aryal, S., Dharmaraj, N., Park, S.Y., Kim, W.D., & Kim, H.Y. In vitro evaluation of poly(caporlactone) grafted dextran (PGD) nanoparticles with cancer cell. J. Mater. Sci. Mater. Med. 19:2157-2163, 2008.
140. Abdelbary, G., & El-Gendy, N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 9:740-747, 2008.
141. Aggarwal, D., & Kaur, I.P. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int. J. Pharm. 290:155-159, 2005.
142. Prabhu, P., Nitish, K.R., Koland, M., Harish, N., Vijayanarayan, K., Dhondge, G., & Charyulu, R. Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system. J. Young Pharm. 2:356-361, 2010.
143. Abdelkader, H., Ismail, S., Kamal, A., & Alany, R.G. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J. Pharm. Sci. 100:1833-1846, 2011.
144. Gan, L., Han, S., Shen, J., Zhu, J., Zhu, C., Zhang, X., and Gan, Y. Self-Assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int. J. Pharm. 396:179-187, 2010.
145. Sankar, A.K.C.V., & Durga, S. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharm. Sci. 48:5-10, 2006.
146. Baeyens, V., Kaltsatos, V., Boisrame, B., Varesio, E., Veuthey, J.L., Fathi, M., Balant, L.P., Gex-Fabry, M., and Gurny, R. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J. Control. Release. 52: 215-220, 1998.
147. Xie, L., Shi, W., Wang, Z., Bei, J., & Wang, S. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea. 20:748-752, 2001.
148. Theng, J.T., Ti, S.E., Zhou, L., Lam, K.W., Chee, S.P., and Tan, D. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest. Ophthalmol. Vis. Sci. 44:4895-4899, 2003.
149. Kagaya, F., Usui, T., Kamiya, K., Ishii, Y., Tanaka, S., Amano, S., & Oshika, T. Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea. 21:200-202, 2002.
150. Tan, D.T., Chee, S.P., Lim, L., Theng, J., & Van Ede, M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology. 108: 2172-2181, 2001.
151. Chang, D.F., Garcia, I.H., Hunkeler, J.D., & Minas, T. Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology. 106:1172-1177, 1999.
152. Kodama, M., Numaga, J., Yoshida, A., Kaburaki, T., Oshika, T., Fujino, Y., Wu, G.S., Rao, N.A., and Kawashima, H. Effects of a new dexamethasone- delivery system (Surodex) on experimental intraocular inflammation models. Graefes Arch. Clin. Exp. Ophthalmol. 241:927-933, 2003.
153. Reis, A., Reinhard, T., Sundmacher, R., Braunstein, S., and Godehardt, E. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 236:785-789, 1998.
154. Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., Fiorentino, D., Nourse, J., & Crabtree, G.R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80:S40-S45, 1996.
155. Shi, W., Liu, T., Xie, L., & Wang, S. FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival. Curr. Eye Res. 30:969-976, 2005.
156. Wong, V.G. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor. US7846468B2; 2010.
157. Robinson, M.R., Csaky, K.G., Nussenblatt, R.B., Smith, J.A., Yuan, P., Sung, C., Fronheiser, M.P., & Kim, H. Ocular therapeutic agent delivery devices and methods for making and using such devices. US0272777; 2010.
158. Jwala, J., Boddu, S.H., Shah, S., Sirimulla, S., Pal, D., and Mitra, A.K. Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J. Ocul. Pharmacol. Ther. 27:163-172, 2011.
159. Vadlapudi, A.D., Vadlapatla, R.K., Kwatra, D., Earla, R., Samanta, S.K., Pal, D., & Mitra, A.K. Targeted lipid based drug conjugates: a novel strategy for drug delivery. Int. J. Pharm. 434:315-324, 2012.
160. Shen, J., Gan, L., Zhu, C., Zhang, X., Dong, Y., Jiang,M., Zhu, J., & Gan, Y. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int. J. Pharm. 412:115-122, 2011.
161. Prasanna, G., Carreiro, S., Anderson, S., Gukasyan, H., Sartnurak, S., Younis, H., Gale, D., Xiang, C., Wells, P., Dinh, D., Almaden, C., Fortner, J., Toris, C., Niesman, M., Lafontaine, J., & Krauss, A. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp. Eye Res. 93:256-264, 2011.
162. Lallemand, F., Furrer, P., Felt-Baeyens, O., Gex-Fabry, M., Dumont, J.M., Besseghir, K., & Gurny, R. A novel watersoluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int. J. Pharm. 295:7-14, 2005.
163. Lallemand, F., Varesio, E., Felt-Baeyens, O., Bossy, L., Hopfgartner, G., & Gurny, R. Biological conversion of a water-soluble prodrug of cyclosporine A. Eur. J. Pharm. Biopharm. 67:555-561, 2007.
164. de Paiva, C.S., Schwartz, C.E., Gjorstrup, P., & Pflugfelder, S.C. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea. 31:1299-1303, 2012.
165. Knapp, S., Bertelmann, E., Hartmann, C., Keipert, S., and Pleyer, U. Intraocular availability of topically applied mycophenolate mofetil in rabbits. J. Ocul. Pharmacol. Ther. 19:181-192, 2003.
166. Mitra, A.K., Velagaleti, P.R., & Grau, U.M. Topical drug delivery systems for ophthalmic use. US 2010/0310642 A1; 2010.
167. Barar, M.A.J., Mortazavi-Tabatabaei, S.A., & Omidi, Y. Ocular drug delivery; Impact of in vitro cell culture models. J. Ophthalmic. Vis. Res. 4:238-252, 2009.